Table 3.
Patient and treatment characteristics
| Cohort | 1 (N=6) |
2 (N=6) |
3 (N=6) |
4 (N=3) |
Total (N=21) |
|---|---|---|---|---|---|
| Age | |||||
| N | 6 | 6 | 6 | 3 | 21 |
| Mean (SD) | 59.3 (7.2) | 63.0 (7.7) | 63.3 (7.7) | 65.3 (1.2) | 62.4 (6.9) |
| Range | (48.0–69.0) | (51.0–71.0) | (54.0–73.0) | (64.0–66.0) | (48.0–73.0) |
| Race | |||||
| White | 5 (83.3%) | 5 (83.3%) | 5 (83.3%) | 2 (66.7%) | 17 (81.0%) |
| Black or African American | 1 (16.7%) | 0 (0.0%) | 1 (16.7%) | 1 (33.3%) | 3 (14.3%) |
| Native Hawaiian or Pacific Islander | 0 (0.0%) | 1 (16.7%) | 0 (0.0%) | 0 (0.0%) | 1 (4.8%) |
| Gender | |||||
| Male | 4 (66.7%) | 4 (66.7%) | 2 (33.3%) | 2 (66.7%) | 12 (57.1%) |
| Female | 2 (33.3%) | 2 (33.3%) | 4 (66.7%) | 1 (33.3%) | 9 (42.9%) |
| HISTOLOGY | |||||
| Adenocarcinoma | 1 (16.7%) | 2 (33.3%) | 3 (50.0%) | 0 (0.0%) | 6 (28.6%) |
| Squamous | 5 (83.3%) | 4 (66.7%) | 3 (50.0%) | 0 (0.0%) | 12 (57.1%) |
| Undifferentiated NSC | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 2 (66.7%) | 2 (9.5%) |
| Other | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (33.3%) | 1 (4.8%) |
| PS | |||||
| 0 | 1 (16.7%) | 3 (50.0%) | 3 (50.0%) | 0 (0.0%) | 7 (33.3%) |
| 1 | 5 (83.3%) | 3 (50.0%) | 3 (50.0%) | 3 (100.0%) | 14 (66.7%) |
| Stage | |||||
| IIIA | 5 (83.3%) | 3 (50.0%) | 4 (66.7%) | 3 (100.0%) | 15 (71.4%) |
| IIIB | 1 (16.7%) | 3 (50.0%) | 2 (33.3%) | 0 (0.0%) | 6 (28.6%) |
| Tumor Volumes (mean) | |||||
| GTV/ITV | 158.6 cc (10.8 – 437.0) | ||||
| PTV | 340.2 cc (82.9 – 1045.4) | ||||
| Key Mean Normal Tissue Doses (Gy) | |||||
| Mean Lung Dose | 13.73 (8.1 – 18.4) | ||||
| Mean Esophagus Dose | 22.0 (7.8 – 37.3) |